Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Nonhematologic Malignancies 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Lung Squamous Cell Carcinoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-hematologic Malignancy 1Neurofibrosarcoma 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Meningeal Neoplasms 1Lymphoma 1Liver Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrent Lung Squamous Cell Carcinoma × sapanisertib × Clear all
NCT02417701 2022-04-05

Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
34 enrolled 10 charts

Recurrent Lung Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡